Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring

Diabetes Care

Volumn 39, Issue 8, 2016, Pages 1416-1423

  Mantovani, Alessandro ^a   Rigamonti, Antonio ^b   Bonapace, Stefano ^c   Bolzan, Bruna ^b   Pernigo, Matteo ^b   Morani, Giovanni ^b   Franceschini, Lorenzo ^b   Bergamini, Corinna ^b   Bertolini, Lorenzo ^c   Valbusa, Filippo ^c   Rigolon, Riccardo ^a   Pichiri, Isabella ^a   Zoppini, Giacomo ^a   Bonora, Enzo ^a   Violi, Francesco ^d   Targher, Giovanni ^a  

^a Section of Endocrinology   (Italy)

^b University and Azienda Ospedaliera ^*  (Italy)

^c SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL;

AGED; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HEMOGLOBIN BLOOD LEVEL; HOLTER MONITORING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONSUSTAINED VENTRICULAR TACHYCARDIA; PAROXYSMAL ATRIAL FIBRILLATION; PAROXYSMAL TACHYCARDIA; PREVALENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; AMBULATORY ELECTROCARDIOGRAPHY; BLOOD; COMPLICATION; CROSS-SECTIONAL STUDY; HEART LEFT VENTRICLE FUNCTION; HEART RATE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR; TACHYCARDIA, VENTRICULAR;

AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TACHYCARDIA, VENTRICULAR; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT;

EID: 84980334568     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0091     Document Type: Article

References (38)

1. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98:483-495
2. Lonardo A, Bellentani S, Argo CK, et al.; Nonalcoholic Fatty Liver Disease Study Group. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 2015; 47:997-1006
3. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10:330-344
4. Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 2015; 100:2231-2238
5. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62(Suppl.):S47-S64
6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350
7. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20:1724-1745
8. Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2014; 24:663-669
9. Hung CS, Tseng PH, Tu CH, et al. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc 2015; 4:e001820
10. Cheriyath P, He F, Peters I, et al. Relation of atrial and/or ventricular premature complexes on a two-minute rhythm strip to the risk of sudden cardiac death (the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011; 107:151-155
11. Simpson RJ Jr, Cascio WE, Schreiner PJ, Crow RS, Rautaharju PM, Heiss G. Prevalence of premature ventricular contractions in a population of African American and white men and women: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2002; 143:535-540
12. Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med 1992; 117:990-996
13. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmiasand mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 1993; 22:1111-1116
14. Qureshi W, Shah AJ, Salahuddin T, Soliman EZ. Long-term mortality risk in individuals with atrial or ventricular premature complexes (results from the Third National Health and Nutrition Examination Survey). Am J Cardiol 2014; 114:59-64
15. Lee YH, Zhong L, Roger VL, et al. Frequency, origin, and outcome of ventricular premature complexes in patients with or without heart diseases. Am J Cardiol 2014; 114:1373-1378
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130:461-470
17. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al.; Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by Association for European Paediatric and Congenital Cardiology (AEPC). Europace 2015; 17:1601-1687
18. Lang RM, Bierig M, Devereux RB, et al.; American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79-108
19. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54:1082-1090
20. Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012; 35:389-395
21. Hallsworth K, Hollingsworth KG, Thoma C, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 2013; 58:757-762
22. VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 2015; 62:773-783
23. Mantovani A, Pernigo M, Bergamini C, et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One 2015; 10:e0135329
24. Targher G, Mantovani A, Pichiri I, et al. Nonalcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 2013; 125:301-309
25. Alonso A, Misialek JR, Amiin MA, et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 2014; 100:1511-1516
26. Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013; 8:e57183
27. Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study). PLoS One 2015; 10:e0142937
28. Markus MR, Meffert PJ, Baumeister SE, et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: the Study of Health in Pomerania (SHIP). Atherosclerosis 2016; 245:123-131
29. Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014; 34:1155-1161
30. Del Ben M, Polimeni L, Carnevale R, et al. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2014; 14:81
31. Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res 2009; 19:319-326
32. Lee DH, Blomhoff R, Jacobs DR Jr Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 2004; 38:535-539
33. Targher G, Byrne CD. Circulating markers of liver function and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 2015; 35:2290-2296
34. Wang K, Li L, Wu Y, et al. Increased serum gamma-glutamyltransferase levels are associated with ventricular instability in type 2 diabetes. Endocrine 2016; 52:63-72
35. Jeong EM, Liu M, Sturdy M, et al. Metabolic stress, reactive oxygen species, and arrhythmia. J Mol Cell Cardiol 2012; 52:454-463
36. Yang KC, Kyle JW, Makielski JC, Dudley SC Jr Mechanisms of sudden cardiac death: oxidants and metabolism. Circ Res 2015; 116:1937-1955
37. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20:7392-7402
38. Byrne CD, Targher G. Time to replace assessment of liver histology with MR-based imagingtests to assess efficacy of interventions for nonalcoholic fatty liver disease. Gastroenterology 2016; 150:7-10